Thermo Fisher Scentific | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 10.86 B

LB filings
2025.08.01 14:43
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 10.86 B, beating the estimate of USD 10.68 B.

EPS: As of FY2025 Q2, the actual value is USD 4.28, beating the estimate of USD 3.9967.

EBIT: As of FY2025 Q2, the actual value is USD 1.709 B.

Life Sciences Solutions

  • Revenues: $2,499 million for the three months ended June 28, 2025, a 6% increase from $2,355 million in the same period in 2024.
  • Segment Income: $919 million for the three months ended June 28, 2025, a 6% increase from $865 million in the same period in 2024.
  • Segment Income Margin: 36.8% for the three months ended June 28, 2025, compared to 36.7% in the same period in 2024.

Analytical Instruments

  • Revenues: $1,728 million for the three months ended June 28, 2025, a 3% decrease from $1,782 million in the same period in 2024.
  • Segment Income: $325 million for the three months ended June 28, 2025, a 26% decrease from $439 million in the same period in 2024.
  • Segment Income Margin: 18.8% for the three months ended June 28, 2025, compared to 24.6% in the same period in 2024.

Specialty Diagnostics

  • Revenues: $1,134 million for the three months ended June 28, 2025, a 2% increase from $1,117 million in the same period in 2024.
  • Segment Income: $306 million for the three months ended June 28, 2025, a 3% increase from $299 million in the same period in 2024.
  • Segment Income Margin: 27.0% for the three months ended June 28, 2025, compared to 26.7% in the same period in 2024.

Laboratory Products and Biopharma Services

  • Revenues: $5,995 million for the three months ended June 28, 2025, a 4% increase from $5,758 million in the same period in 2024.
  • Segment Income: $825 million for the three months ended June 28, 2025, an 11% increase from $745 million in the same period in 2024.
  • Segment Income Margin: 13.8% for the three months ended June 28, 2025, compared to 12.9% in the same period in 2024.

Outlook

Thermo Fisher Scientific Inc. expects its GAAP effective tax rate in 2025 to be between 6% and 8% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits.

Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.